Abstracts tagged "Mortality"

Abstract Number: 0685 • ACR Convergence 2024
KL-6 and IL-18 Biomarkers in Systemic Sclerosis-associated Interstitial Lung Disease: Enhancing Prognostic Insights into Early Detection, Progression, Lung Volume Changes,and Mortality Risk
cristiana sieiro santos¹, Miriam Retuerto², Laura Sierra², Sara Calleja Antolín², Elena Bollo de Miguel², Jose Ordas Martínez³, Paula Pérez García², Pedro Baenas², Clara Moriano Morales², Javier de la Calle Lorenzo² and Elvira Díez Álvarez⁴, ¹Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ²Complejo Asistencial Universitario de León, León, Spain, ³Complejo Asistencial Universitario de Leon, Leon, ⁴Complejo Asistencial Universitario de León, Leon, Spain
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of mortality in scleroderma, underscoring the critical demand for reliable biomarkers. KL-6 and IL-18, have been…
Abstract Number: 1327 • ACR Convergence 2024
Association of Rheumatoid Arthritis and Frailty Status with Mortality in Patients with Renal Cell Carcinoma
Sherwin Novin¹, Sarah Holt², Maya Swaminathan³, Jonathan Wright², John Gore², Kimme Hyrich⁴, Sizheng Zhao⁵, Jeffrey Sparks⁶, Una Makris⁷, Maria Suarez-Almazor⁸, Petros Grivas², Sarah Psutka² and Namrata Singh⁹, ¹University of Washington, Seattle, WA, ²University of Washington, Seattle, ³MultiCare, Newcastle, WA, ⁴Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ⁵Centre for Musculoskeletal Research, The University of Manchester, Liverpool, United Kingdom, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ⁷UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁸MD Anderson Cancer Center, Houston, TX, ⁹University of Washington, Bellevue, WA
Background/Purpose: Few studies have evaluated clinical outcomes and prognosis of patients with cancer with and without rheumatoid arthritis (RA). Renal cell carcinoma (RCC) is particularly…
Abstract Number: 2241 • ACR Convergence 2024
Associations Between Disease Activity, Physical Function and Anti-rheumatic Medications with All-cause Mortality in Rheumatoid Arthritis (RA): Data from a Canadian RA Registry
Mohammad Movahedi¹, Angela Cesta², Xiuying Li², Bindee Kuriya³, Sibel Aydin⁴, Ed Keystone⁵, Janet Pope⁶ and Claire Bombardier⁷, and OBRI investigators, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²UHN, Toronto, ON, Canada, ³University of Toronto - Toronto, Toronto, ON, Canada, ⁴Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁵Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁶University of Western Ontario, London, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of hospitalizations and mortality due to RA itself, associated comorbidities, and treatment-related complications. The purpose…
Abstract Number: 0686 • ACR Convergence 2024
The Role of Inflammation in Systemic Sclerosis: CRP-Associated Phenotypes and Prognostic Implications
cristiana sieiro santos¹, Miriam Retuerto², Paula Pérez García², Jose Ordas Martínez³, Pedro Baenas², Clara Moriano Morales² and Elvira Díez Álvarez⁴, ¹Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ²Complejo Asistencial Universitario de León, León, Spain, ³Complejo Asistencial Universitario de Leon, Leon, ⁴Complejo Asistencial Universitario de León, Leon, Spain
Background/Purpose: Systemic sclerosis (SSc) manifests through a diverse interplay of inflammatory, fibrotic, and vascular alterations, intricately entwined in its pathogenesis, which encompasses immune system dysregulation,…
Abstract Number: 1400 • ACR Convergence 2024
Disease Modifying Anti-rheumatic Drug Use and Association with Survival in Patients with Rheumatoid Arthritis and Newly Diagnosed Lung Cancer
Varun Nandakumar¹, Aaron Baraff², Alexander Peterson², Nicholas Smith³, Jennifer Barton⁴, Ann O'Hare², Christopher Li⁵, Noel Weiss³ and Namrata Singh⁶, ¹AIIMS, New Delhi, Delhi, India, ²VA PUGET SOUND SEATTLE, Seattle, WA, ³University of Washington, Seattle, WA, ⁴VA Portland Health Care System/OHSU, Portland, OR, ⁵University of Washington, Seattle, ⁶University of Washington, Bellevue, WA
Background/Purpose: Despite the significant therapeutic benefits of various disease modifying anti-rheumatic drugs (DMARDs) in RA, concerns remain regarding their safety, particularly their potential impact on…
Abstract Number: 2250 • ACR Convergence 2024
Cause Specific Mortality Differs in Rheumatoid Arthritis by Sex and Seropositivity
Elena Joerns¹, Ryan Lennon², Cynthia Crowson², Andrea Lopez-ruiz², Roslin Jose George², Vanessa Kronzer², John Davis² and Elena Myasoedova², ¹Mayo Clinic, Rochester, ²Mayo Clinic, Rochester, MN
Background/Purpose: Persons with rheumatoid arthritis (RA) have an increased risk of mortality compared to the general population. Seropositivity has been shown to be associated with…
Abstract Number: 0689 • ACR Convergence 2024
Arrhythmic Burden, Myocardial Markers, and Long-term Survival in Distinct Cardiac Magnetic Resonance Subsets of Systemic Sclerosis
Silvia Laura Bosello¹, Enrico De Lorenzis², Giacomo De Luca³, Antonio Tonutti⁴, veronica Batani⁵, Pier Giacomo Cerasuolo⁶, Gerlando Natalello⁷, Lucia Lanzo⁶, Gabriella Alonzi⁶, Silvia Fiore⁶, Stefano Di Murro⁶, Andrea Zoli⁶, Valentina Boni⁶, Riccardo Marano⁸, Francesca Augusta Gabrielli⁹, Francesco Del Galdo¹⁰, Dan Knight¹¹, Vivek Muthurangu¹¹, Christopher Denton¹², Maria De Santis⁴, Marco Matucci Cerinic⁵ and Maria Antonietta D'Agostino¹³, ¹Unit of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ²Catholic University of the Sacred Heart, Roma, Rome, Italy, ³Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Milan, Milan, Italy, ⁴Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano, Italy, ⁵Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, ⁶Division of Rheumatology, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁷Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Rome, Italy, ⁸Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, Diagnostic Imaging Area, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy, ⁹Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ¹⁰University of Leeds, Leeds, United Kingdom, ¹¹UCL Department of Cardiac MRI, University College London (Royal Free Campus), London, United Kingdom, ¹²University College London, Northwood, United Kingdom, ¹³Division of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Università Cattolica del Sacro Cuore, Rome, Italy
Background/Purpose: Cardiac involvement in Systemic Sclerosis (SSc) is widely recognized as heterogeneous and, when clinically evident, it is associated with a poor prognosis. Recently, five…
Abstract Number: 1522 • ACR Convergence 2024
Impact of Thrombocytopenia on In-hospital Mortality and Healthcare Resource Utilization in Patients with Systemic Lupus Erythematosus: An Analysis of the National Inpatient Sample Database 2020
Soziema Salia¹, Ufuoma Mamoh², Gilava Hedayati², Joseph Atarere³, Raymond Wadie⁴, Boniface Mensah³, Joan Morny⁵ and Indira Acharya⁶, ¹MedStar Union Memorial Hospital, Towson, MD, ²Medstar Union Memorial Hospital, Baltimore, MD, ³Department of Internal Medicine, MedStar Union Memorial Hospital, Baltimore, MD, ⁴Department of Internal Medicine, Cayuga Medical Center, Ithaca, NY, ⁵Piedmont Athens Regional Medical Center, Athens, GA, ⁶Medstar Internal Medicine Residency Program, Baltimore, MD
Background/Purpose: Thrombocytopenia is associated with Systemic Lupus Erythematosus (SLE) and occurs at various stages of the disease. It is reported in an estimated 10% to 40% of…
Abstract Number: 2297 • ACR Convergence 2024
Mortality and Its Predictor Variables in Patients with Sjögren Disease: Data from SjögrenSER-Pros Prospective Registry
Olga Rusinovich¹, Zulema Plaza², Mónica Fernández Castro³, José Rosas-Gómez de Salazar⁴, Victor Manuel Martinez Taboada⁵, Alejandro Olive⁶, Raúl Menor Almagro⁷, Belen Serrano Benavente⁸, Judit Font Urgelles⁹, Angel Garcia-Aparicio¹⁰, Sara Manrique-Arija¹¹, Jesus A García-Vadillo¹², Ruth Lopez Gonzalez¹³, Javier Narvaez-García¹⁴, Maria Beatriz Rodriguez¹⁵, Carlos Galisteo¹⁶, Jorge Gonzalez Martin¹⁷, Paloma Vela-Casasempere¹⁸, Cristina Bohorquez¹⁹, MARIA CELIA ERAUSQUIN ARRUABARRENA²⁰, MARIA BEATRIZ PAREDES ROMERO²¹, ELENA Aurrecoechea²², Sheila Melchor Diaz²³, José María Pego-Reigosa²⁴, Sergi Heredia Martin²⁵, Clara Moriano²⁶, Maria Angeles Blazquez Canamero²⁷, Paula Estrada-Alarcón²⁸, enrique Judez²⁹, Joaquin María Belzunegui:³⁰, Consuelo Ramos³¹, Marta de la Puerta³², Fernando Sánchez-Alonso³³ and Jose Luis Andreu³⁴, ¹Hospital Universitario Puerta de Hierro Majadahonda., Boadilla del Monte, Spain, ²Fundacion Española de Reumatología, Madrid, Spain, ³Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Madrid, Spain, ⁴Hospital Marina Baixa, PALMA DE MALLORCA, Comunidad Valenciana, Spain, ⁵Facultad de Medicina. Universidad de Cantabria, Santander, Cantabria, Spain, ⁶Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, ⁷Department of Rheumatology, Hospital Jerez de la Frontera, Jerez de la Frontera, Spain, ⁸Hospital Gregorio Marañón, Madrid, Madrid, Spain, ⁹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁰Hospital Universitario de Toledo, Toledo, Spain, ¹¹Biomedical Research Institute of Malaga (IBIMA)-Bionand Platform, Department of Rheumatology, Regional University Hospital of Malaga, Malaga, Spain, ¹²H La Princesa, Madrid, Spain, ¹³Complejo Hospitalario de Zamora, Zamora, Castilla y Leon, Spain, ¹⁴Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁵H Universitario de Canarias, La Laguna- Tenerife, Canarias, Spain, ¹⁶Hospital Universitario Parc Taulí, Sabadell, Spain, ¹⁷H Madrid Norte SanChinarro, Madrid, Spain, ¹⁸Hospital General Universitario Alicante, Alicante, Spain, ¹⁹Hospital Universitario Príncipe de Asturias, Alcalá De Henares, Madrid, Spain, ²⁰Gob Canarias, Tenerife, Canarias, Spain, ²¹H Infanta Sofia, Madrid, Spain, ²²HOSPITAL SIERRALLANA, CANTABRIA, Spain, ²³12 de Octubre University Hospital, Madrid, Spain, ²⁴Galicia Health Service (SERGAS), Vigo, Spain, ²⁵Hospital de L’Hospitalet, Barcelona, Spain, ²⁶Hospital León, LEON, Spain, ²⁷Hospital Ramon y Cajal, Madrid, Madrid, Spain, ²⁸Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²⁹H de Albacete, Albacete, Spain, ³⁰H de Donostia, Donostia-San Sebasti, Spain, ³¹Hospital Universitario Virgen de Valme, Sevilla, Spain, ³²Spanish Society of Rheumatology, Madrid, Spain, ³³Sociedad Española de Reumatología, Madrid, Spain, ³⁴Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain
Background/Purpose: It remains debated if patients with Sjögren´s disease (SjD) have a greater mortality risk. The objective of our study was to determine the magnitude…
Abstract Number: 0694 • ACR Convergence 2024
A Unified Vascular Phenotype Score Identifies Systemic Sclerosis Endotypes and Predicts Prognostic Outcomes: Results from the EUSTAR Database
Stefano Di Donato¹, Michael Hughes², John Pauling³, Marco Matucci-Cerinic⁴, Lesley-Anne Bissell⁵, Edward Jude⁶, Christopher Denton⁷, Yannick Allanore⁸, Marie-Elise Truchetet⁹ and Francesco Del Galdo¹⁰, and EUSTAR collaborators, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ²Tameside and Glossop Integrated NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom, ³North Bristol NHS Trust, Bristol, United Kingdom, ⁴University San Raffaele Milano, Milano, Milan, Italy, ⁵Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶Tameside and Glossop Integrated Care NHS Foundation Trust, Ashton-under-Lyne, United Kingdom, ⁷University College London, Northwood, United Kingdom, ⁸Université Paris Cité, Paris, France, ⁹Bordeaux University Hospital, Bordeaux, France, ¹⁰University of Leeds, Leeds, United Kingdom
Background/Purpose: Vascular dysfunction is pivotal in Systemic Sclerosis (SSc) pathogenesis, leading to somatic vascular signs such as pitting scars, Digital Ulcers (DUs), telangiectasia as well…
Abstract Number: 1528 • ACR Convergence 2024
Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: National Inpatient Sample Analysis
Maria Romero Noboa¹, Almurtada Razok², Husam El Sharu³ and Rafaella Litvin², ¹University of Alabama at Birmingham, Chicago, IL, ²John H Stroger Jr Hospital of Cook County, Chicago, IL, ³East Carolina University, Greenville, NC
Background/Purpose: Systemic Lupus Erythematosus (SLE) can lead to a range of pulmonary complications, including Pulmonary Arterial Hypertension (PAH), which affects between 0.5% and 17.5% of…
Abstract Number: 2392 • ACR Convergence 2024
Clinical Characteristics and Outcomes of Systemic Lupus Erythematosus When Accompanying Myositis: A Retrospective Real-Life Study
Güllü Sandal Uzun¹ and David Isenberg², ¹University College London, London, England, United Kingdom, ²University College London, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) and idiopathic inflammatory myositis (IIM) are chronic, potentially severe autoimmune diseases, that may affect many organs/ systems. In this study, we…
Abstract Number: 0695 • ACR Convergence 2024
Prognostic Value of Serum Type I Interferon in Predicting Morbi-Mortality Outcomes in Systemic Sclerosis: Insights from the STRIKE Basket Cohort
Stefano Di Donato¹, Marco Minerba², Enrico De Lorenzis³, Collette Hartley⁴, Lesley-Anne Bissell⁵, Rebecca Ross⁶ and Francesco Del Galdo⁴, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ²Campus Bio-Medico University of Rome, Taranto, United Kingdom, ³Catholic University of the Sacred Heart, Roma, Rome, Italy, ⁴University of Leeds, Leeds, United Kingdom, ⁵Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶Medicine and Health, University of Leeds, Leeds, United Kingdom
Background/Purpose: Systemic Sclerosis (SSc) encompasses limited cutaneous (lc)SSc and diffuse cutaneous (dc)SSc, with lcSSc affecting more than 60% of patients and dcSSc associated being burdened…
Abstract Number: 1614 • ACR Convergence 2024
Mortality in Patients with Giant Cell Arteritis in Spain: Results from the ARTESER Registry
Juan Molina-Collada¹, Marta Domínguez-Álvaro², Rafael Benito Melero-Gonzalez³, Eugenio De Miguel⁴, Maite Silva-Diaz⁵, Jesús Alejandro Valero⁶, Ismael Gonzalez⁷, Julio Sánchez-Martín⁸, Javier Narvaez-García⁹, Joan Calvet¹⁰, Ivette Casafont-Solé¹¹, José A Román Ivorra¹², Selene Labrada-Arrabal¹³, Margarida Vasques Rocha:¹⁴, Carlota L Iñiguez:¹⁵, Maria Sagrario Bustabad Reyes¹⁶, Cristina Campos-Fernández¹⁷, María Alcalde Villar:¹⁸, Antonio Juan-Mas¹⁹ and Ricardo Blanco-Alonso²⁰, and ARTESER Project Collaborative Group, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³CHU Ourense, O Carballino, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁶Hospital Universitario Donosti. Donostia, Spain, Donosti, Spain, ⁷Complejo Asistencial Universitario de Leon, León, Spain, ⁸Hospital Universitario 12 de Octubre, Madrid, Spain, ⁹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁰Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA) (UAB), 08208 Sabadell, Spain, Barcelona, Spain, ¹¹Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, Barcelona, Spain, ¹²Hospital Universitari i Politècnic La Fe, Valencia, Spain, Valencia, Spain, ¹³Hospital del Mar, Barcelona, Spain, ¹⁴Hospital Universitario Araba, Vitoria, Spain, ¹⁵Hospital Universitario Lucus Augusti, Galicia, Spain, Galicia, Spain, ¹⁶Hospital Universitario de Canarias, La Laguna - Tenerife, Spain, ¹⁷Consorci Hospital General Universitari de València, Comunitat Valenciana, Spain, Valencia, Spain, ¹⁸Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Spain, ¹⁹Hospital Universitari Son Llàtzer, Mallorca, Spain, ²⁰Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: The question of survival in epidemiologic studies on giant cell arteritis (GCA) remains unclear to date, with notable heterogeneity in both the mortality rate…
Abstract Number: 2393 • ACR Convergence 2024
Demographic Differences in Trends of Systemic Lupus Erythematosus In-hospital Patient Outcomes
Joan Morny¹, Abdultawab Shaka², Terrylyna Baffoe-Bonnie³ and Hafeez Shaka⁴, ¹Piedmont Athens Regional Medical Center, athens, GA, ²Windor University School of Medicine, Saint Kitts and Nevis, U.S. Virgin Islands, ³Medstar Health Union Memorial Hospital, Baltimore, MD, ⁴Stroger Jr Hospital, Chicago, IL
Background/Purpose: The care of patients with Systemic Lupus Erythematosus (SLE) is challenging, and with the emergency of newer disease modifying medications, clinical outcomes in these…

1
2
3
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].